Nina Paleologos to Neoplasm Recurrence, Local
This is a "connection" page, showing publications Nina Paleologos has written about Neoplasm Recurrence, Local.
Connection Strength
0.472
-
Intravenous thrombolysis for ischemic stroke in recurrent oligodendroglioma: a case report. J Stroke Cerebrovasc Dis. 2014 May-Jun; 23(5):1235-8.
Score: 0.074
-
Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. J Neurooncol. 2012 07; 108(3):491-8.
Score: 0.067
-
Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2011 Jun; 13(6):660-8.
Score: 0.063
-
Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. Oncologist. 2010; 15(12):1329-34.
Score: 0.061
-
Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2011 Jan; 13(1):143-51.
Score: 0.061
-
The role of retreatment in the management of recurrent/progressive brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010 Jan; 96(1):85-96.
Score: 0.057
-
A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma. Neuro Oncol. 2020 10 14; 22(10):1505-1515.
Score: 0.030
-
Myeloablative chemotherapy for recurrent aggressive oligodendroglioma. Neuro Oncol. 2000 04; 2(2):114-9.
Score: 0.029
-
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009 Oct 01; 27(28):4733-40.
Score: 0.014
-
Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol. 2003 Nov 15; 21(22):4151-6.
Score: 0.009
-
Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. J Clin Oncol. 1998 Jun; 16(6):2202-12.
Score: 0.006